9th Oct 2014 11:15
LONDON (Alliance News) - Vectura Group PLC said Thursday that partner Sandoz has been granted marketing authorisation by the Portugal Health Authority for AirFluSal Forspiro, an inhaler for patients with asthma and chronic obstructive pulmonary disease.
The approval covers 50-250 milligram 50-500 milligram doses.
The product has already been launched in five European countries and has marketing authorisation in 10 European countries as well as South Korea and Mexico.
Sandoz is the generics division of Swiss pharmaceutical company Novartis AG.
Vectura shares were trading 0.2% lower at 122.50 pence Thursday.
By Rowena Harris-Doughty; [email protected]; @rharrisdoughty
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L